BIOX Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp., together with its subsidiaries, develops and commercializes crop productivity solutions in Argentina, Brazil, the rest of Latin America, and internationally. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The company offers biological crop nutrition products comprising seed inoculants under the Rizoliq and UHC brands, biofertilizers, and biostimulants; biocontrol products, including bionematicides, biofungicides, and bioinsecticides; crop nutrition and crop protection products, such as micro-beaded fertilizers and adjuvants; and seed germplasms, GMO and non-GMO traits, and ready-to-use seed treatment pack solutions for healthier and higher yielding crops. It also provides fungicide products under the Rizoderma brand; Rizofos for foliar applications; therapies, herbicides, and baits; and bio-inductors, crop health products, and biological and micro granulated fertilizers. In addition, the company licenses its HB4 seed trait for drought tolerance in wheat and soybean seeds. It sells its products to blue-chip companies and industry leaders, large distributors, co-ops, dealers, large farmers, and individual growers through distributors and dealers. The company was founded in 2001 and is headquartered in Rosario, Argentina.…
Industry Peers
Agricultural InputsKey Statistics
About Bioceres Crop Solutions (NASDAQ: BIOX)
›
Bioceres Crop Solutions (NASDAQ: BIOX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Agricultural Inputs industry, part of the Basic Materials sector, and reports about 562 employees.
The shares were at 0.1829 USD on 19 November 2026, down 90.5% over 52 weeks. Its 52-week range is 0.1703 USD to 2.030 USD: the price is 91.0% below the high and 7.4% above the low.
Its market capitalisation is 11.67M USD.
Bioceres Crop Solutions reports return on equity of -50.1%, an operating margin of -8.1% and revenue down 30.4% year over year.
Its debt exceeds its cash by 224.60M USD, a debt-to-equity ratio of 1.05. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.